Shield Therapeutics PLC Investor Presentation (0605R)
March 03 2021 - 8:40AM
UK Regulatory
TIDMSTX
RNS Number : 0605R
Shield Therapeutics PLC
03 March 2021
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Investor Presentation
London, UK - 3 March 2021: Shield Therapeutics plc (LSE: STX), a
commercial stage pharmaceutical company, announces that it will
provide a live presentation on Tuesday 9 March 2021 at 4.00pm
covering the recent GBP25m fundraise and Open Offer to raise up to
GBP4.2m and the US market opportunity ahead.
CEO, Tim Watts will present and introduce Brian Groch, who will
run the Company's US commercial operations. Brian has some 30
years' commercial experience gained from working with a range of
pharmaceutical and biotechnology companies.
The presentation will be hosted through the digital platform
Investor Meet Company. Investors can sign up to Investor Meet
Company for free and request to meet Shield Therapeutics plc via
the following link:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of regulations and information already
disclosed to the market through regulatory notifications. A
recording of the presentation, a PDF of the slides used, and
responses to the Q&A session will be available on the Investor
Meet Company platform afterwards. No new price sensitive
information will be disclosed, and a PDF of the presentation will
be uploaded to the Company's website.
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO)
Peel Hunt LLP - Nominated Adviser, Joint
Broker and Bookrunner +44 (0) 20 7148 8900
James Steel / Oliver Jackson (Investment
Banking)
Jock Maxwell Macdonald / Sohail Akbar
(ECM)
finnCap Ltd - Joint Broker and Bookrunner +44 (0) 20 7220 0500
Geoff Nash / Matthew Radley (Corporate
Finance)
Alice Lane / Charlotte Sutcliffe (ECM)
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol) (R), a novel, stable, non-salt
based oral therapy for adults with iron deficiency with or without
anaemia. Shield is quoted on AIM (STX). For more information about
Shield, please see www.shieldtherapeutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUOSURAVUORAR
(END) Dow Jones Newswires
March 03, 2021 08:40 ET (13:40 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024